InvestorsHub Logo
Followers 829
Posts 119609
Boards Moderated 14
Alias Born 09/05/2002

Re: None

Monday, 06/19/2017 11:43:31 AM

Monday, June 19, 2017 11:43:31 AM

Post# of 427
EU approves NVS’ Rituxan FoB, called Rixathon:

https://www.novartis.com/news/media-releases/sandoz-receives-approval-europe-rixathonr-biosimilar-rituximab-treat-blood

This is the second Rituxan FoB in Europe; Celltrion's Truxima was the first.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVS News